The billion $ molecule has been createdInvestors, consider the potential parallel to Vertex, where a billion-dollar molecule yielded a remarkable 8765.78% return. Now, there's a scientific breakthrough in a realm beyond common peoples comprehension. C60, proven non-toxic and life-extending in animals, represents a transformative discovery in drug development (source: https://pubmed.ncbi.nlm.nih.gov/22498298/).
Explore current fullerene products at https://wizardsciences.com/. Voyageur (Voy) stands to generate early cash through C60 olive oil, boasting the world's lowest carbon cost. Even before plant construction, recent news indicates RC can supply carbon to Voy. Health products, such as C60 olive oil, can gain rapid approval.
Examining fullerene MRI studies with Gd, Va, Fe reveals that encapsulating atoms within a C60 ball enhances their properties. For instance, it makes Gd in MRI contrast 100 times more effective, reducing the amount of Gd, Va, or Fe in drug administration. Once safety in animals is proven, the market cap could increase by hundreds of millions leading to a billion $ value on each drug they successfully complete. The critical question: can the body eliminate carbon mettofullerene? Answering this propels the value to an unprecedented level.
Voyageur's venture into drug development is for certain, attracting close attention from Big Pharma. As Voyageur is the only pathway into pharma carbon drug development. With the billion-dollar molecule secured, the focus shifts to proving the worth of the potential billion-dollar vanadium contrast drug. Success in this endeavor opens doors to creating numerous new drugs for imaging and drug delivery in many fields including cancer treatment. They stated iodine fullerene, if they accomplish this, there is no way GE/Bracco etal will allow Voyageur to take over the contrast media market.
Anticipate a stock surge beyond $10 with successful drug development. For shareholders, this presents a potential retirement stock. Accumulate and hold, optimizing RRSP accounts. Voyageur is a pharmaceutical game-changer. Barium contrast sales are imminent, and financing for Frances Creek is likely post-economic validation. This incredible news positions Voyageur for significant growth. Investors, take note – the market's awakening to this story is inevitable, that day is coming. All of us current shareholders are in for a wild ride soon. Good luck!